Fulcrum Therapeutics reports Q4 EPS (31c), consensus (29c)

As of December 31, 2024, cash, cash equivalents, and marketable securities were $241.0M, as compared to $236.2M as of December 31, 2023. The increase is due to the $80.0M upfront payment received from Sanofi (SNY) in the second quarter of 2024, partially offset by cash used to fund operating activities in 2024, the company noted. “We are entering 2025 with strong momentum behind our lead program, pociredir, for the treatment of sickle cell disease. Having recently enrolled the 10th patient in the 12 mg dose cohort, we remain on track to share important clinical data this year, including data from the 12 mg dose cohort in mid-2025 and data from the 20 mg dose cohort by the end of the year. Based on both its mechanism of action and data generated in the Phase 1b trial to date, pociredir has the potential to ameliorate SCD symptoms by increasing fetal hemoglobin, which could transform the current standard of care by offering a differentiated oral treatment option for patients with SCD,” said CEO Alex Sapir.